Isis Earns $9 Mln Milestone Payment From Biogen Idec

(RTTNews) - Isis Pharmaceuticals, Inc. (ISIS) said it has earned a $9 million milestone payment from Biogen Idec (BIIB) related to advancing the ongoing pivotal Phase 3 study evaluating ISIS-SMN in infants with spinal muscular atrophy or SMA.

ENDEAR, a Phase 3 study of ISIS-SMN, is a randomized, double-blind, sham-procedure controlled thirteen month study in about 110 infants diagnosed with SMA.

The study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMN with a primary endpoint of survival or time to permanent ventilation. Additional efficacy endpoints are also included in the study.